Association of transanal minimally invasive surgical approach with oncologic outcomes over conventional transanal excision for early-stage rectal cancer: An analysis of the US Rectal Cancer Consortium.

Authors

null

Emilie Warren

Emory University, Atlanta, GA;

Emilie Warren , Adriana C. Gamboa , Caroline Medin , Samantha Hendren , Scott E. Regenbogen , Jennifer Holder-Murray , Matthew Kalady , Aslam Ejaz , Alexander Hawkins , Paul Wise , Matthew Silviera , Shishir K. Maithel , Glen C. Balch

Organizations

Emory University, Atlanta, GA; , University of Michigan, Ann Arbor, MI; , Division of Colon and Rectal Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA; , Ohio State University Wexner Medical Center, Columbus, OH; , The Ohio State University Wexner Medical Center, Columbus, OH; , Vanderbilt Univ. Medical Center, Nashville, TN; , Washington University in St. Louis, St. Louis, MO; , Section of Colon & Rectal Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO; , Winship Cancer Institue, Emory University, Atlanta, GA; , Division of Colon & Rectal Surgery, Department of Surgery, Emory University, Atlanta, GA;

Research Funding

Other Government Agency
Katz Foundation, Chester P Rochfort Scholarship, Winship Cancer Institute of Emory University

Background: For early-stage rectal cancer, minimally invasive surgical (MIS) approaches such as transanal endoscopic microsurgery (TEM) and transanal minimally invasive surgery (TAMIS) have not been widely adopted over conventional transanal excision (TAE). Direct comparisons are lacking. Our aim was to compare oncologic and perioperative outcomes between the two approaches. Methods: We identified patients with Tis or T1 tumors who underwent TAE or MIS (TEM or TAMIS) between 2007-2017 from the US Rectal Cancer Consortium database. Patients who received neoadjuvant therapy were excluded. Primary outcomes were rate of recurrence and recurrence-free survival (RFS). Results: Of 1881 patients, 89 met inclusion criteria: 44 TAE and 45 MIS (20 TEM, 25 TAMIS). Median age was similar between groups (63.5 years TAE vs 61 years MIS; p=0.582). Patients in each group had similar functional status and tumor size (1.86 cm TAE vs 1.79 cm MIS, p=0.837). The majority of patients had tumors ≤ 6 cm from the anal verge (75.7% TAE vs 65.5% MIS, p=0.544). The TAE group had a 10.3% margin positive rate versus 0% in the MIS group (p=0.049). There was a lower incidence of recurrence in the MIS group (4.5%) compared to TAE (26%, p=0.01); all recurred locally except for one in the TAE group. Median follow-up time was 23.7 months. On Kaplan-Meier analysis, MIS approach was associated with improved 5-year RFS (86.4%, p=0.005) and local RFS (86.4%, p=0.01), versus TAE (46.9% and 50.5%, respectively). On univariate cox regression analysis, lymphovascular invasion was associated with worse RFS (HR 4.23, p=0.033) and local RFS (HR 5.26, p=0.02), while MIS approach was associated with improved RFS (HR 0.15, p=0.015) and local RFS (HR 0.17, p=0.023). On multivariable cox regression, only MIS approach remained associated with improved RFS (HR 0.09, p=0.028) and local RFS (HR 0.11, p=0.045). Perioperative complication and readmission rates were equal between the two groups. Conclusions: In patients with Tis and T1 rectal cancers who undergo local excision, an MIS approach (TEM or TAMIS) is associated with a decreased rate of recurrence and improved RFS and local RFS compared to TAE, with no significant difference in perioperative complication rate. The MIS approach should be more frequently incorporated into standard practice.

Cox regression analysis of recurrence-free survival.
UnivariateMultivariable
p- valueHR (95% CI)p-valueHR (95% CI)
BMI0.2031.05 (0.97- 1.14)--
Tumor Size0.9821.01 (0.61- 1.65)--
Distance from the anal verge
Ref: ≤ 6 cm
> 6 cm0.5450.62 (0.13 – 2.92)--
Lymphovascular Invasion
Ref: absent
Present 0.033 4.23 (1.12- 15.93) 0.1182.99 (0.76- 11.84)
Surgical Approach
Ref: TAE
MIS (TEM/TAMIS) 0.015 0.15 (0.03- 0.69) 0.028 0.09 (0.01- 0.77)

Ref: reference. HR: hazard ratio. CI: confidence interval.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 145)

DOI

10.1200/JCO.2023.41.4_suppl.145

Abstract #

145

Poster Bd #

H4

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Local excision to enhance organ preservation in rectal cancer after favorable response to total neoadjuvant therapy.

First Author: Aron Bercz

First Author: Caroline Medin

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Recurrence in the pelvic side wall after lateral lymph node dissection for rectal cancer.

First Author: Misato Takao